Real-World Evaluation of Compl-AI for Predicting Early Medication Dropout in Opioid Use Disorder Treatment

The goal of this observational study is to learn whether the Compl-AI model can accurately predict who is likely to stop their medication for opioid use disorder (MOUD) early in adults receiving real-world treatment for opioid use disorder (OUD).

The main questions it aims to answer is:

can the model accurately predict early discontinuation of MOUD?

Because this study has no comparison groups, all participants receive their usual MOUD as part of routine care. Researchers will observe how participants engage with treatment and how well Compl-AI predicts their outcomes.

Participants will complete 4 visits, including a questionnaire about personal experiences during first visit and questions about their substance use and treatment history.

During the monthly study visits, the researchers will record in particular the attendance at MOUD medication visits, the medication adherence and any treatment discontinuation.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Opioid Use Disorder Chemically-Induced Disorders Mental Disorders Narcotic-Related Disorders Opioid-Related Disorders Substance-Related Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

SOAP MAT, LLC - Central, San Diego, California, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Ability to understand and provide written informed consent.
Male and female participant 18 years of age at the time of consent.
Participant with OUD based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).
Eligible to receive MOUD per site standard of care or currently receiving MOUD initiated prior to study enrollment.

Exclusion criteria

Cognitive impairment that precludes the ability to provide written informed consent.
Already enrolled in another study/program.

Treatment and study plan

Primary outcomes

Proportion of attended MOUD medication visits

Time frame: Observation period will be three (3) months.
Proportion of prescribed doses taken

Time frame: Observation period will be three (3) months.

Study contacts

Contact information is provided by the study sponsor or research team.

Chantal Gossuin

CONTACT

[email protected]

+32(0)71140200

Laura Onckelinx

CONTACT

[email protected]

+32(0)71140200

Sponsors and collaborators

Lead sponsor

Tools4Patient

Other

Registry information

Official study title

Real-World Assessment of Compl-AI in Predicting Early Discontinuation of Medication for Treatment of Opioid Use Disorder (MOUD) in Community and Specialty Treatment Programs

Important dates

Study start: 2026
Primary completion: 2026
Study completion: 2026
First posted: Mar 9, 2026
Registry last updated: Mar 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting